This is a preprint.
High-order brain interactions in ketamine during rest and task: A double-blinded cross-over design using portable EEG
- PMID: 38562802
- PMCID: PMC10984031
- DOI: 10.21203/rs.3.rs-3954073/v1
High-order brain interactions in ketamine during rest and task: A double-blinded cross-over design using portable EEG
Update in
-
High-order brain interactions in ketamine during rest and task: a double-blinded cross-over design using portable EEG on male participants.Transl Psychiatry. 2024 Jul 27;14(1):310. doi: 10.1038/s41398-024-03029-0. Transl Psychiatry. 2024. PMID: 39068157 Free PMC article. Clinical Trial.
Abstract
In a double-blinded cross-over design, 30 adults (mean age = 25.57, SD = 3.74; all male) were administered racemic ketamine and compared against saline infusion as a control. Both task-driven (auditory oddball paradigm) and resting-state EEG were recorded. HOI were computed using advanced multivariate information theory tools, allowing us to quantify nonlinear statistical dependencies between all possible electrode combinations. Results: Ketamine increased redundancy in brain dynamics, most significantly in the alpha frequency band. Redundancy was more evident during the resting state, associated with a shift in conscious states towards more dissociative tendencies. Furthermore, in the task-driven context (auditory oddball), the impact of ketamine on redundancy was more significant for predictable (standard stimuli) compared to deviant ones. Finally, associations were observed between ketamine's HOI and experiences of derealization. Conclusions: Ketamine appears to increase redundancy and genuine HOI across metrics, suggesting these effects correlate with consciousness alterations towards dissociation. HOI represents an innovative method to combine all signal spatial interactions obtained from low-density dry EEG in drug interventions, as it is the only approach that exploits all possible combinations from different electrodes. This research emphasizes the potential of complexity measures coupled with portable EEG devices in monitoring shifts in consciousness, especially when paired with low-density configurations, paving the way for better understanding and monitoring of pharmacological-induced changes.
Conflict of interest statement
FB, MI, HN, BM and LR-D are employees and shareholders of Cumulus Neuroscience Ltd. MW is a member of the following advisory boards and has given presentations to the following companies: Bayer AG, Germany; Boehringer Ingelheim, Germany; and Biologische Heilmittel Heel GmbH, Germany. MW has further conducted studies with institutional research support from HEEL and Janssen Pharmaceutical Research for a clinical trial (IIT) on ketamine in patients with MDD, unrelated to this investigation. MW did not receive any financial compensation from the companies mentioned above. DLB and PO were employees and shareholders of Takeda Pharmaceuticals at the time of the original study. The other authors declare that they have no competing interests.
Figures




References
-
- Krystal J. H. et al. Subanesthetic Effects of the Noncompetitive NMDA Antagonist, Ketamine, in Humans: Psychotomimetic, Perceptual, Cognitive, and Neuroendocrine Responses. Arch. Gen. Psychiatry 51, 199–214 (1994). - PubMed
-
- Murrough J. W., Abdallah C. G. & Mathew S. J. Targeting glutamate signalling in depression: progress and prospects. Nat. Rev. Drug Discov. 16, 472–486 (2017). - PubMed
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources